赤羽 智子 (アカハネ トモコ)

Akahane, Tomoko

写真a

所属(所属キャンパス)

医学部 産婦人科学教室(婦人科) (信濃町)

職名

特任助教(有期)

学位 【 表示 / 非表示

  • 医学博士

免許・資格 【 表示 / 非表示

  • 医学博士

 

論文 【 表示 / 非表示

  • Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance

    Akahane T., Hirasawa A., Imoto I., Okubo A., Itoh M., Nanki Y., Yoshihama T., Tominaga E., Aoki D.

    Human Cell (Human Cell)  33 ( 1 ) 272 - 282 2020年01月

    ISSN  09147470

     概要を見る

    © 2019, Japan Human Cell Society and Springer Japan KK, part of Springer Nature. Malignant peritoneal mesothelioma (MPeM) is a rare and aggressive form of malignant mesothelioma. Sufficient biological tools for studying the functional characteristics of this cancer have not been developed. Therefore, in this study, a novel human cancer cell line, KOG-1, was established from ascites fluids isolated from a 39-year-old Japanese woman with pemetrexed-resistant MPeM. Cells were dendritic or linear immediately after thawing, showed a jigsaw puzzle-like and spindle arrangement during growth, and formed monolayers without contact inhibition in two-dimensional (2D) culture. The population doubling time was 13.7 h. Karyotypic and molecular genetic analyses showed that chromosome numbers ranged from 62 to 142, with a peak of 73 with complicated copy number alterations. No germline BAP1 pathogenic variant was detected. Cells expressed various tumor markers of mesothelioma, such as calretinin, podoplanin, and Wilms tumor 1 (WT-1). Drug sensitivity and resistance testing with a set of 36 drugs using 2D and three-dimensional (3D) culture models demonstrated that KOG-1 cells showed high and low sensitivity to pemetrexed under 2D and 3D culture conditions, respectively, whereas control ovarian cancer cell lines showed low sensitivity to pemetrexed under both culture conditions. This newly established cell line will be a valuable biological resource to expand the feasibility of functional studies as well as drug testing for potential therapeutic purposes in MPeM.

  • GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy

    Yoshihama Tomoko, Fukunaga Koya, Hirasawa Akira, Nomura Hiroyuki, Akahane Tomoko, Kataoka Fumio, Yamagami Wataru, Aoki Daisuke, Mushiroda Taisei

    Oncotarget 9 ( 51 ) 29789 - 29800 2018年07月

    ISSN  1949-2553

     概要を見る

    <p>Purpose: To find genetic variants that predicted toxicity and/or efficacy of paclitaxel plus carboplatin combination therapy (TC therapy). Patients and methods: In a retrospective case-control study, we analyzed 320 patients who had received TC therapy for gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, and cervical cancers) and collected their germline DNA. We performed a comprehensive pharmacogenomic analysis using a targeted resequencing panel of 100 pharmacogenes. For 1,013 variants passing QC, case-control association studies and survival analyses were conducted. Results: GSTP1 rs1695 showed the smallest p value for hematotoxicity association, and the 105Ile wild type allele had a significantly higher risk of severe hematotoxicity (neutropenia G4, thrombocytopenia ≥ G3 and anemia ≥ G3) than the 105Val allele (p=0.00034, odds ratio=5.71 (95% confidence interval:1.77-18.44)). Next, we assessed 5-year progression-free survival (PFS) and overall survival (OS) in 56 advanced ovarian cancer patients who received tri-weekly TC as a first-line chemotherapy. Patients with the 105Ile/105Ile genotype showed significantly better PFS (p=0.00070) and OS (p=0.0012) than those with the 105Ile/105Val or 105Val/105Val genotype. Conclusion: Our study indicates that the GSTP1 rs1695 105Ile/105Ile genotype is associated with both severe hematotoxicity and high efficacy of TC therapy, identifying a possible prognostic indicator for patients with TC therapy.</p>

  • GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: A comprehensive analysis using targeted resequencing of 100 pharmacogenes

    Yoshihama T., Fukunaga K., Hirasawa A., Nomura H., Akahane T., Kataoka F., Yamagami W., Aoki D., Mushiroda T.

    Oncotarget (Oncotarget)  9 ( 51 ) 29789 - 29800 2018年07月

     概要を見る

    © Yoshihama et al. Purpose: To find genetic variants that predicted toxicity and/or efficacy of paclitaxel plus carboplatin combination therapy (TC therapy). Patients and methods: In a retrospective case-control study, we analyzed 320 patients who had received TC therapy for gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, and cervical cancers) and collected their germline DNA. We performed a comprehensive pharmacogenomic analysis using a targeted resequencing panel of 100 pharmacogenes. For 1,013 variants passing QC, case-control association studies and survival analyses were conducted. Results: GSTP1 rs1695 showed the smallest p value for hematotoxicity association, and the 105Ile wild type allele had a significantly higher risk of severe hematotoxicity (neutropenia G4, thrombocytopenia ≥ G3 and anemia ≥ G3) than the 105Val allele (p=0.00034, odds ratio=5.71 (95% confidence interval:1.77-18.44)). Next, we assessed 5-year progression-free survival (PFS) and overall survival (OS) in 56 advanced ovarian cancer patients who received tri-weekly TC as a first-line chemotherapy. Patients with the 105Ile/105Ile genotype showed significantly better PFS (p=0.00070) and OS (p=0.0012) than those with the 105Ile/105Val or 105Val/105Val genotype. Conclusion: Our study indicates that the GSTP1 rs1695 105Ile/105Ile genotype is associated with both severe hematotoxicity and high efficacy of TC therapy, identifying a possible prognostic indicator for patients with TC therapy.

  • Erratum

    Masuda Kenta, Hirasawa Akira, Irie-Kunitomi Haruko, Akahane Tomoko, Ueki Arisa, Kobayashi Yusuke, Yamagami Wataru, Nomura Hiroyuki, Kataoka Fumio, Tominaga Eiichiro, Banno Kouji, Susumu Nobuyuki, Aoki Daisuke

    Japanese Journal of Clinical Oncology 47 ( 5 ) 473 2017年05月

    ISSN  0368-2811

  • Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer

    Masuda Kenta, Hirasawa Akira, Irie-Kunitomi Haruko, Akahane Tomoko, Ueki Arisa, Kobayashi Yusuke, Yamagami Wataru, Nomura Hiroyuki, Kataoka Fumio, Tominaga Eiichiro, Banno Kouji, Susumu Nobuyuki, Aoki Daisuke

    Japanese Journal of Clinical Oncology 47 ( 5 ) 401 - 406 2017年05月

    ISSN  0368-2811

     概要を見る

    <p>Background: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients.Method: Ovarian or endometrial cancer patients were recruited for this study. After informed consent was obtained, participants completed the questionnaire. Genetic risks were assessed from the data of each patient's questionnaire by Society of Gynecologic Oncology guideline. Clinical and pathological findings were compared between the genetic risk groups.Results: A total of 105 patients were identified with ovarian cancer and 56 patients with endometrial cancer eligible for this study. According to the Society of Gynecologic Oncology guideline, of the 105 ovarian cancer patients, 25 patients (23%) had a 20-25% risk and three patients (2.9%) had a 5-10% risk of hereditary breast and ovarian cancer syndrome. A further 22 patients (21%) had a 5-10% risk of Lynch syndrome. Two patients (1.9%) met the Amsterdam criteria II. Of 56 endometrial cancer patients, 24 patients (42.9%) had a 5-10% risk of Lynch syndrome. The endometrial cancer patients with genetic risk of Lynch syndrome were younger (mean age: 47.79) at diagnosis compared to patients without a genetic risk of Lynch syndrome (mean age: 57.91).Conclusions: In this study, we were able to show that the newly designed questionnaire is a useful tool for evaluating cancer family history along with Society of Gynecologic Oncology criteria or Amsterdam criteria II. When considering the risk of Lynch syndrome for a patient with ovarian cancer, it is important to collect a second and third relative's family history.</p>

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

研究発表 【 表示 / 非表示

  • UGT1A1遺伝子多型と血清ビリルビン値の関連および婦人科イリノテカン療法副作用への関与に関する検討

    平沢 晃、赤羽 智子、長西秀樹、大久保啓介、齋藤康一郎、座間 猛、野村弘行、津田浩史、進 伸幸、後田奈緒美、谷川原祐介、青木大輔

    第29回日本臨床薬理学会 (東京) , 

    2008年12月

    ポスター発表

  • 塩酸イリノテカンによるがん個別化治療を目指したUGT1A1遺伝子多型と血清ビリルビン値に関する検討

    平沢 晃、赤羽 智子、山上 亘、野村弘行、阪埜浩司、津田浩史、長西秀樹、大久保啓介、齋藤康一郎、座間 猛、谷川原祐介、進 伸幸、青木大輔

    第67回日本癌学会学術総会(シンポジウム) (名古屋) , 

    2008年10月

    口頭発表(一般)

  • 子宮内膜症から卵巣明細胞癌への癌化についての検討

    赤羽 智子、関沢明彦、奥田剛、長塚正晃、木村武彦、岡井崇

    日本産科婦人科学会 (横浜) , 

    2006年04月

    ポスター発表

競争的研究費の研究課題 【 表示 / 非表示

  • 卵巣癌発癌機構の解明と微量核酸解析による癌早期発見を目指した新規検査法の開発

    2019年04月
    -
    2022年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 赤羽 智子, 基盤研究(C), 補助金,  研究代表者

  • 卵管上皮細胞を起源とする卵巣癌発癌機構の解明

    2016年04月
    -
    2019年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 赤羽 智子, 基盤研究(C), 補助金,  研究代表者

受賞 【 表示 / 非表示

  • 第67回日本産科婦人科学会優秀演題賞授賞

    2015年04月